Isthmus Partners LLC Sells 8,129 Shares of iRadimed Corporation $IRMD

Isthmus Partners LLC trimmed its stake in shares of iRadimed Corporation (NASDAQ:IRMD) by 13.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,611 shares of the medical equipment provider’s stock after selling 8,129 shares during the period. Isthmus Partners LLC owned about 0.40% of iRadimed worth $4,923,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC boosted its stake in iRadimed by 88.6% in the 4th quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock worth $6,848,000 after purchasing an additional 33,072 shares during the period. Algert Global LLC increased its holdings in iRadimed by 87.5% during the 3rd quarter. Algert Global LLC now owns 50,797 shares of the medical equipment provider’s stock worth $3,615,000 after purchasing an additional 23,710 shares in the last quarter. UBS Group AG raised its stake in shares of iRadimed by 389.9% in the 3rd quarter. UBS Group AG now owns 25,433 shares of the medical equipment provider’s stock valued at $1,810,000 after purchasing an additional 20,242 shares during the period. Punch & Associates Investment Management Inc. bought a new stake in shares of iRadimed in the third quarter valued at about $1,210,000. Finally, RFG Advisory LLC bought a new stake in shares of iRadimed in the fourth quarter valued at about $1,594,000. 92.34% of the stock is owned by institutional investors.

iRadimed Price Performance

iRadimed stock opened at $86.44 on Friday. The company has a market cap of $1.10 billion, a price-to-earnings ratio of 47.24 and a beta of 0.90. The firm has a 50-day moving average of $93.68 and a 200-day moving average of $94.67. iRadimed Corporation has a one year low of $50.88 and a one year high of $107.90.

iRadimed (NASDAQ:IRMD) last released its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The business had revenue of $21.98 million for the quarter, compared to the consensus estimate of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, sell-side analysts expect that iRadimed Corporation will post 1.52 earnings per share for the current year.

iRadimed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 15th will be paid a dividend of $0.20 per share. The ex-dividend date is Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s dividend payout ratio is currently 43.72%.

Insider Activity

In other news, CEO Roger E. Susi sold 4,411 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $83.92, for a total value of $370,171.12. Following the completion of the sale, the chief executive officer owned 2,180,000 shares of the company’s stock, valued at approximately $182,945,600. This represents a 0.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 60,000 shares of company stock worth $5,661,603. Corporate insiders own 36.80% of the company’s stock.

Analysts Set New Price Targets

IRMD has been the subject of several recent research reports. Weiss Ratings upgraded iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 6th. Lake Street Capital restated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. Freedom Capital raised iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Finally, Roth Mkm reaffirmed a “buy” rating and set a $120.00 price target on shares of iRadimed in a research note on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.